Sergio Lira, MD, PhD

Mount Sinai
New York, NY
USA
Biographical Sketch: Sergio Lira received his MD from the Universidade Federal de Pernambuco in Brazil and his PhD in Physiology and Pharmacology from the University of California at San Diego. He did his postdoctoral training at the Roche Institute for Molecular Biology in Nutley, NJ. After his postdoctoral training he worked for 11 years in the pharma sector, first at Bristol-Myers Squibb and then at Schering-Plough. He is currently the The Leona M. and Harry B. Hemsley Charitable Trust Professor of Immunology at the Icahn School of Medicine at Mount Sinai in New York, where is the Director of the Immunology Institute. His research focuses on the role of immune cells and the microbiome in mucosal inflammation and cancer. He has organized international meetings in this field, including the 2003 Keystone Symposium on Chemokines and the 2006 Gordon Research Conference on Chemotactic Cytokines. He was elected to the Henry Kunkel Society in 2006 and to the Association of American Physicians in 2008.

Any personal financial relationships? No

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 06/25/2015 by Sergio Lira

Papers:
Neonatal Innate Lymphoid Cells in the Intestine and Inflammatory

	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".